Cryosurgery in aggressive, benign, and low-grade malignant bone tumours

Veth, R.P.H.; Schreuder, Bart H. W.; Beem, H. Van; Pruszczyński, M; Rooy, Jacky de

doi:10.1016/s1470-2045(04)01710-3

Cited by 67 publications

(72 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In situ tumour destruction with cryo, radiofrequency or laser ablation has received increasing attention as a treatment modality for focal cancer (Ruers et al, 2001;Ruers and Bleichrodt, 2002;Curley, 2003;Erce and Parks, 2003;Veth et al, 2005). However, little is known regarding the induction of immune responses after in situ tumour destruction or the fate of the generated tumour debris.…”

Section: Discussionmentioning

confidence: 99%

Efficient loading of dendritic cells following cryo and radiofrequency ablation in combination with immune modulation induces anti-tumour immunity

et al. 2006

View full text Add to dashboard Cite

Dendritic cells (DC) are professional antigen-presenting cells that play a pivotal role in the induction of immunity. Ex vivo-generated, tumour antigen-loaded mature DC are currently exploited as cancer vaccines in clinical studies. However, antigen loading and maturation of DC directly in vivo would greatly facilitate the application of DC-based vaccines. We formerly showed in murine models that radiofrequency-mediated tumour destruction can provide an antigen source for the in vivo induction of anti-tumour immunity, and we explored the role of DC herein. In this paper we evaluate radiofrequency and cryo ablation for their ability to provide an antigen source for DC and compare this with an ex vivo-loaded DC vaccine. The data obtained with model antigens demonstrate that upon tumour destruction by radiofrequency ablation, up to 7% of the total draining lymph node (LN) DC contained antigen, whereas only few DC from the conventional vaccine reached the LN. Interestingly, following cryo ablation the amount of antigen-loaded DC is almost doubled. Analysis of surface markers revealed that both destruction methods were able to induce DC maturation. Finally, we show that in situ tumour ablation can be efficiently combined with immune modulation by anti-CTLA-4 antibodies or regulatory Tcell depletion. These combination treatments protected mice from the outgrowth of tumour challenges, and led to in vivo enhancement of tumour-specific T-cell numbers, which produced more IFN-g upon activation. Therefore, in situ tumour destruction in combination with immune modulation creates a unique, 'in situ DC-vaccine' that is readily applicable in the clinic without prior knowledge of tumour antigens.

show abstract

Section: Discussionmentioning

confidence: 99%

Efficient loading of dendritic cells following cryo and radiofrequency ablation in combination with immune modulation induces anti-tumour immunity

et al. 2006

View full text Add to dashboard Cite

show abstract

“…Cryosurgery after intralesional curettage is much promising in grade 1 chondrosarcoma, with at least similar results of marginal excision in term of oncological control and mostly better than those of wide excisions in terms of functional results. [34][35][36] A vicious cycle has been described in osteolytic metastasis; tumor cells release osteolytic mediators and bone resorption release growth factors which enhance tumor cell growth and further release of osteolytic mediators. 9 One can speculate that this vicious cycle may also occur in the case of the primary bone tumor.…”

Section: Discussionmentioning

confidence: 99%

Zoledronic acid slows down rat primary chondrosarcoma development, recurrent tumor progression after intralesional curretage and increases overall survival

Gouin

Ory

Redini

et al. 2006

Intl Journal of Cancer

View full text Add to dashboard Cite

Chondrosarcoma is a difficult musculoskeletal tumor to treat. Surgical treatment leads to severe disability, with high rates of local recurrence and life threat. No adjuvant therapy is effective in differentiated chondrosarcomas. Bisphosphonates (BPs) are a class of molecules which is effective in malignant bone diseases. The aim of the present study was to determine the effects of zoledronic acid (ZOL) on chondrosarcoma tumor progression. ZOL was tested in vivo (s.c. 100 lg/kg, twice a week) in a rat chondrosarcoma model and in vitro (10 27 -10 24 M) on cells derived from this model. Two types of animal models were assessed, the first simulated development after intralesional curettage, the second nonoperative development of the tumor. Cell proliferation, caspase-1, -3 activities and cell cycle analysis were studied. The results revealed that ZOL slows down primary tumor development, tumor progression after intralesional curretage and increases overall survival. ZOL inhibits cell proliferation and increases cell death, with no significant variation of caspase-1 and -3 activities and cell cycle profiles. The present study demonstrates for the first time that in addition to surgery, the therapy of chondrosarcoma with BPs might be beneficial. Because of these first results, new therapeutic approaches of chondrosarcoma must be considered, mainly for low grade chondrosarcoma when disabling operation is planned and when only intralesional resection can be undertaken. ' 2006 Wiley-Liss, Inc.

show abstract

“…Acceptable oncologic and functional results have been observed in patients with grade 1 chondrosarcoma treated with curettage and cryosurgery alone [64,69]. However, local recurrence is not unusual if there is inadequate resection [68,69].…”

Section: Surgerymentioning

confidence: 99%

“…However, local recurrence is not unusual if there is inadequate resection [68,69]. Wide excision is performed in higher grade chondrosarcomas, and occasionally in grade 1 chondrosarcoma.…”

Section: Surgerymentioning

confidence: 99%

Insights into Enchondroma, Enchondromatosis and the risk of secondary Chondrosarcoma. Review of the literature with an emphasis on the clinical behaviour, radiology, malignant transformation and the follow up

Herget¹,

Strohm²,

Rottenburger³

et al. 2014

neo

View full text Add to dashboard Cite

Cryosurgery in aggressive, benign, and low-grade malignant bone tumours

Cited by 67 publications

References 64 publications

Efficient loading of dendritic cells following cryo and radiofrequency ablation in combination with immune modulation induces anti-tumour immunity

Efficient loading of dendritic cells following cryo and radiofrequency ablation in combination with immune modulation induces anti-tumour immunity

Zoledronic acid slows down rat primary chondrosarcoma development, recurrent tumor progression after intralesional curretage and increases overall survival

Insights into Enchondroma, Enchondromatosis and the risk of secondary Chondrosarcoma. Review of the literature with an emphasis on the clinical behaviour, radiology, malignant transformation and the follow up

Contact Info

Product

Resources

About